A Randomized Trial of Modified-Release Versus Immediate-Release Tolvaptan in ADPKD.

Kidney Int Rep · 2020 · PMC7271942 · PMID 32518861

Europe PMC DOI

hedged sentences

—

closest p

—

boldest claim

The sentences

a decreasing trendno p-value reported

Pharmacodynamics Urine osmolality showed a decreasing trend with increasing tolvaptan dose.

also in 47,180 other papers

showed a trendno p-value reported

Urinary Burden The mean 24-hour urine volume on treatment showed a trend to increase with tolvaptan dose, with values ranging from approximately 4750 ml for tolvaptan MR 20 mg to 7400 ml for tolvaptan MR 120 mg and IR 90+30 mg ( Figure 5 a).

also in 53,322 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.